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Abstract
Background: Stratifying patients with a sore throat into the probability of having an underlying bacterial or viral
cause may be helpful in targeting antibiotic treatment. We sought to assess the diagnostic accuracy of signs and
symptoms and validate a clinical prediction rule (CPR), the Centor score, for predicting group A b-haemolytic
streptococcal (GABHS) pharyngitis in adults (> 14 years of age) presenting with sore throat symptoms.
Methods: A systematic literature search was performed up to July 2010. Studies that assessed the diagnostic
accuracy of signs and symptoms and/or validated the Centor score were included. For the analysis of the
diagnostic accuracy of signs and symptoms and the Centor score, studies were combined using a bivariate
random effects model, while for the calibration analysis of the Centor score, a random effects model was used.
Results: A total of 21 studies incorporating 4,839 patients were included in the meta-analysis on diagnostic
accuracy of signs and symptoms. The results were heterogeneous and suggest that individual signs and symptoms
generate only small shifts in post-test probability (range positive likelihood ratio (+LR) 1.45-2.33, -LR 0.54-0.72). As a
decision rule for considering antibiotic prescribing (score ≥ 3), the Centor score has reasonable specificity (0.82,
95% CI 0.72 to 0.88) and a post-test probability of 12% to 40% based on a prior prevalence of 5% to 20%. Pooled
calibration shows no significant difference between the numbers of patients predicted and observed to have
GABHS pharyngitis across strata of Centor score (0-1 risk ratio (RR) 0.72, 95% CI 0.49 to 1.06; 2-3 RR 0.93, 95% CI
0.73 to 1.17; 4 RR 1.14, 95% CI 0.95 to 1.37).
Conclusions: Individual signs and symptoms are not powerful enough to discriminate GABHS pharyngitis from
other types of sore throat. The Centor score is a well calibrated CPR for estimating the probability of GABHS
pharyngitis. The Centor score can enhance appropriate prescribing of antibiotics, but should be used with caution
in low prevalence settings of GABHS pharyngitis such as primary care.
Background
Upper respiratory tract infections such as acute pharyn-
gitis represent a substantial portion of the cases seen in
primary care [1]. Although the cause of acute pharyngi-
tis in the majority of patients is viral, approximately 5%
to 17% is caused by a bacterial infection, often b-
haemolytic streptococci [2]. A number of serotypes of
b-haemolytic streptococci can cause pharyngitis in
humans, however, antibiotics are only recommended in
US and UK guidelines for treating patients with group
A b-haemolytic streptococcal (GABHS) pharyngitis [3,4].
Antibiotics reduce the risk of complications (for exam-
ple, peritonsillar abscess, bacteraemia, acute glomerulo-
nephritis and rheumatic fever), as well as reducing the
duration of symptoms and spread of the disease [5-7].
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‘reference standard’ for the diagnosis of streptococcal
pharyngitis [8,9]. This test has a number of limitations
in practice; it is relatively expensive; the laboratory tests
take 1-2 days leading to delays in starting treatment;
and excessive false positive results in asymptomatic
pharyngeal carriers may lead to over treatment [10,11].
To enhance the appropriate prescribing of antibiotics
without performing cultures on all patients a number of
clinical prediction rules (CPRs) have been developed
over the last 40 years to distinguish streptococcal phar-
yngitis from pharyngitis by other causes [12-15]. CPRs
are evidence-based tools that allow clinicians to stratify
patients according to their probability of having a parti-
cular disorder. They can also be used to provide a
rational basis for treatment.
The most widely recognised CPR for GABHS pharyn-
gitis is the Centor score [16]. The Centor score consists
of four signs and symptoms (Table 1) and is recom-
mended in clinical guidelines from the American Col-
lege of Physicians-American Society of Internal
Medicine (ACP/ASIM) and Centers for Disease Control
and Prevention (CDC) in the US. The ACP/ASIM
recommends (a) empirical antibiotic treatment of adults
with at least three of four Centor criteria and no treat-
ment for all others; or (b) empirical treatment of adults
with all four criteria, rapid antigen detection test
(RADT) of patients with three or two criteria, and sub-
sequent treatment of those with positive test results and
no treatment for all others [17]. In the UK, the National
Institute for Health and Clinical Excellence (NICE)
recommend that clinicians consider immediate treat-
ment with antibiotics for patients who have three or
more Centor criteria [4]. A modified version of the Cen-
tor criteria is also used in New Zealand as part of a
guideline for sore throat management [14,18].
The pretest probability of GABHS pharyngitis is
reported to peak between the ages of 5 and 10 years
[15]. The prevalence in children is reported to be
around 20% to 25% while in adults it is between 5% to
10% [12]. This review will focus on adults (≥ 15 years of
age), the age group of the cohort in which the Centor
score was derived.
Although a considerable amount of research has
already been devoted to streptococcal pharyngitis, it
remains unclear which symptoms and signs have the
most discriminatory power and whether the most widely
recognised rule, the Centor score, is valid in a range of
clinical settings. The aim of this systematic review was
to analyse the current evidence on the usefulness of
individual signs and symptoms in assessing the risk of
streptococcal pharyngitis in adults, to assess the diag-
nostic accuracy of the Centor score as a decision rule
for antibiotic treatment (discrimination analysis) and to
perform a meta-analysis on validation studies of the
Centor score (calibration analysis).
Methods
Data sources and searches
An electronic search was performed using a search filter
developed by Haynes et al. [19,20]. This preset filter
(search string: (predict*[tiab] OR predictive value of
tests[mh] OR scor*[tiab] OR observ*[tiab] OR observer
variation[mh]) is available in the PubMed database and
has a reported sensitivity of 96% and specificity of 79%
[19]. PubMed was searched from January 1966 to 26
July 2010 and EMBASE from January 1980 to 26 July
2010. A combination of the phrases ‘streptococcal phar-
yngitis’ and ‘sore throat’ (maps to: ((’streptococcus’[-
MeSH Terms] OR ‘streptococcus’[All Fields] OR
‘streptococcal’[All Fields]) AND (’pharyngitis’[MeSH
Terms] OR ‘pharyngitis’[All Fields])) OR (’pharyngitis’[-
MeSH Terms] OR ‘pharyngitis’[All Fields] OR (’sore’[All
Fields] AND ‘throat’[All Fields]) OR ‘sore throat’[All
Fields])’ were entered into the filter. The search was lim-
ited by using a combination of phrases for ambulatory
care; ‘general practice’, ‘family practice’, ‘emergency
department’ and ‘primary care’ (maps to: (’general prac-
tice’[MeSH Terms] OR (’general’[All Fields] AND ‘prac-
tice’[All Fields]) OR ‘general practice’[All Fields]) OR
(’family practice’[MeSH Terms] OR (’family’[All Fields]
AND ‘practice’[All Fields]) OR ‘family practice’[All
Fields]) OR ((’emergencies’[MeSH Terms] OR ‘emergen-
cies’[All Fields] OR ‘emergency’[All Fields]) AND
department[All Fields]) OR (’primary health care’[MeSH
Terms] OR (’primary’[All Fields] AND ‘health’[All
Fields] AND ‘care’[All Fields]) OR ‘primary health car-
e’[All Fields] OR (’primary’[All Fields] AND ‘care’[All
Fields]) OR ‘primary care’[All Fields])). The search was
supplemented by hand checking references of filtered
papers, searching Google Scholar, the Cochrane Library
and the MEDION database (University of Maastricht).
No restrictions were placed on language.
Table 1 The Centor score
Symptoms Points Score Post-test
probability
Tonsillar exudates 1 0 2.5%
Tender anterior cervical
adenopathy
1 1 6.5%
Absence of cough 1 2 15.4%
History of fever (> 38.0°C) 1 3 31.6%
4 55.7%
Patients receive a point for the presence or absence of signs and symptoms.
Each patient is assigned a score between 0 and 4 which is associated with a
post-test probability as calculated by Centor and colleagues [16]. (The post-
test probability values presented are the mean of the original probability
intervals reported by Centor and colleagues.)
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Two investigators (JA and KOB) independently evalu-
ated the title, abstract and subsequently full text of all
articles for inclusion and any disagreements were
resolved by discussion with a third investigator (WSC).
Studies were included if participants were recruited
upon first presentation from an ambulatory care setting,
had a sore throat as their main presenting complaint,
and were ≥ 15 years of age. Both prospective and retro-
spective studies were included in the review.
Each included study assessed the diagnostic accuracy
of signs and symptoms and/or validated the Centor
score. The reference standard for all studies was a throat
culture. If this information was not available in publica-
tions, data were sought from corresponding authors.
The majority of studies separated positive results for
group A b-haemolytic streptococcal infection from non-
group A infection (mostly group C and G). Patients who
were positive with a non-group A streptococcal infec-
tion were counted as negatives when the data were
pooled. Additional file 1 has more information on the
reported proportions of non-group A infection.
Data extraction and quality assessment
Data were extracted by two investigators (JA and KOB)
independently, and any discrepancies were resolved by
discussion.
The Quality Assessment of Diagnostic Accuracy Studies
(QUADAS) tool was used to assess the quality of each
included study [21]. This tool was modified to ensure
appropriateness to this study. Items 3, 4, 6, 7, 12 and 13
were omitted from the original QUADAS tool as they
were not relevant to this study and four questions
extracted from other reviews were added; ‘Was the
hypothesis clearly defined’, ‘Were the patients selected in a
non-biased manner’, ‘Were the statistical tests for the
main outcomes adequate’ and ‘Were data on observer var-
iation reported and within acceptable range’ (Figure 1)
[22,23]. Quality assessment was performed independently
by three researchers (JA, KOB and WSC). Each article was
assessed by at least two researchers with disagreements
resolved by review and discussion with the third
researcher.
Data synthesis and analysis
Diagnostic accuracy of signs and symptoms
Data were extracted and 2 × 2 tables constructed for the
following signs and symptoms: (i) absence of cough, (ii)
fever, (iii) anterior cervical adenopathy, (iv) tender anterior
cervical adenopathy, and (v) any exudates (either tonsillar
exudate or pharyngeal exudate or any exudate). Although
some studies examined other signs and symptoms, those
chosen for inclusion in this diagnostic test accuracy study
were the most consistently studied signs and symptoms.
Review Manager v.5.0.16 [24] and a bivariate random
effects model [25] were used to analyse the extracted
data. The analysis consisted of (a) summary sensitivities
and specificities calculated for each sign and symptom,
(b) positive and negative likelihood ratios and (c) sum-
mary receiver operating characteristic (SROC) curves.
The bivariate random effects model accounts for the
bivariate nature of sensitivity and specificity as well as
the within-study and between-study variability [25]; as
this approach is not available in Review Manager
v.5.0.16, the Stata package metandi [26] was used for
this part of the analysis.
Diagnostic accuracy of the Centor score
As the Centor score is recommended by guidelines as a
decision aid for empirical antibiotic use [4,17], we
explored the diagnostic accuracy of the score at different
cut points. In all, 12 studies were included in this analy-
sis [14,27-37]; 3 studies were excluded from this analysis
as they excluded patients with a Centor score less than
2 [38-40]. The analysis consisted of (a) summary sensi-
tivities and specificities and (b) positive and negative
likelihood ratios, calculated using a random effect bivari-
ate model (using the Stata package metandi [26]). Post-
test probabilities are presented for the Centor score at a
range of pretest probabilities.
Calibration of the Centor score
We assessed calibration of the Centor score across four
levels (0-1, 2, 3 and 4). Calibration enables visual and
quantitative assessment of how well a CPR performs
across different levels of risk [41]. The predicted number
of patients with GABHS pharyngitis (based on the prob-
ability calculated in the derivation study [16], Table 1)
were compared with the observed number of patients
with GABHS pharyngitis in each validation study. The
data were pooled and analysed using a Mantel-Haenszel
random effects model and risk ratios (RRs) reported. The
total heterogeneity across studies was quantified using
the I
2 index. The Centor score data were analysed in
groups (score 0-1, 2-3 and 4) as the ACP/ASIM guide-
lines recommend treatment options on the basis of these
categories [17]. In the majority of studies, data were avail-
able for all score categories; the predicted was calculated
for each score category and the results added together to
form the group data (0-1, 2-3). For example, Atlas et al.
[27] reported 11 patients had a score of 0 and 44 had a
score of 1. We calculated the number predicted to have
GABHS pharyngitis based on the probabilities reported
in Table 1, 11 × 2.5% + 44 × 6.5% = 0.275 + 2.86 = 3.135.
In one case [29], data were only available for the score
group (0-1, 2-3); in this case the mean post-test probabil-
ity for the group (mean of 2.5% and 6.5% = 4.5%) was
used to calculate the predicted score.
We carried out a subgroup analysis to discover the
influence of disease prevalence on the performance of
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tion study [16]). Poses and colleagues suggested the use
of the likelihood ratio formulation of Bayes’ theorem to
adjust for prevalence [42]. In our review, the method of
Poses et al. was applied to the meta-analysis data and
the effect on the results is discussed.
The Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) statement was followed
during the course of this study [43].
Results
Study identification
A flow diagram of our search strategy is presented in
Figure 2. Two researchers screened all potential articles.
They agreed that the full text of 58 articles should be
examined. In all, 35 relevant studies were identified, 18
of which included only adults whilst the other 17
included both adults and children. Only 4 of the 18
adult only studies reported all required data
[16,28,39,44]. The authors of the remaining adult papers
were written to for additional data. In all, 13 authors
responded and 8 studies were subsequently included
[13,27,29,37,38,40,45,46]. After writing to the authors of
mixed adult and children papers, 13 responses were
received and the data for adults only were included for
8 of these studies [14,31-36,47]. Data from one thesis
was included in the analysis and was obtained through a
personal communication [30].
Data on signs and symptoms were available in all of
the 21 included studies, which included 4,839 patients
[13,14,16,27-40,44-47]. A total of 15 studies also pro-
vided data on the Centor score, which included 2,900
patients [14,27-40]. The characteristics of each included
study are summarised in Additional file 1.
Study description
The included studies came from a variety of settings and
countries. In all, 19 of the studies took place in a pri-
mary care setting; the other 2 studies took place in an
emergency department setting [16,44]. Five studies were
based in the USA [13,16,27,44,46], while nine were
based in Europe [28,31,33,35,38-40,45,47], three in
Canada [14,34,36], two in New Zealand [30,32], and one
each in Thailand [37] and Israel [29].
The prevalence of GABHS pharyngitis in the studies
was highly variable, ranging from 4.7% [40] to 37.6%
[38]. Three studies excluded all patients with a Centor
score less than 2 [38-40]. Three studies included
patients with broader presenting symptoms of upper
respiratory tract infection [14,37,47].
Study quality
The result of the quality assessment is shown in Figure
1. The overall quality of the included studies was good.
The spectrum of patients was generally appropriate and
representative of the patients who would receive the test
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Observer variation bias
Appropriate statistical analysis
Patient slection bias
Defined hypothesis
Withdrawals 
Diagnostic review bias
Test review bias
Reference standard details
Clinical test details
Partial verification bias
Selection Criteria
Patients spectrum
Quality Score, %
Yes No Unclear
Figure 1 Reviewer judgements of methodological quality of included studies according to use of modified Quality Assessment of
Diagnostic Accuracy Studies (QUADAS) tool.
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signs and symptoms being studied were generally clearly
described. Quality items on test and diagnostic review
bias scored well. This was due to the result of the throat
culture being unknown at the time of the first visit
when the signs and symptoms were recorded, and the
throat culture being analysed by an independent labora-
tory. Observer variation in assessing signs and symp-
toms (question 12) was poorly reported.
Diagnostic accuracy of individual symptoms and signs
The sensitivity, specificity, positive likelihood ratio (+
LR) and -LR are reported in Table 2. Absence of cough
and tender cervical adenopathy had a higher sensitivity
than specificity (sensitivity 0.74, specificity 0.49 and sen-
sitivity 0.67, specificity 0.59 respectively), while fever and
any exudates had a higher specificity than sensitivity
(sensitivity 0.50, specificity 0.70 and sensitivity 0.57 and
specificity 0.74 respectively). ‘Any exudates’ had the
Discarded 102 duplicates
(N=405)
Studies excluded after 
reading title (N=232)
Studies excluded after 
reading abstract (N=115)
Full text retrieved (N=58)
Included (N=18) 
Citation searching (N=2)
Included studies (N=21)
Google Scholar,
287 hits (N=0)
Potentially relevant articles 
identified in Embase (N=271)
Excluded (N=40) 
- No signs or symptoms or score used (N=2)
- No relevant patient group (N=2)
- Did not contain suitable clinical data (N=6)
- Outcome measures not suitable (N=8)
- No throat culture for all patients (N=5)
- Used data from another study (N=3)
- No contact possible with authors (N=4)
- Articles not retrievable (N=2)
After correspondence with authors:
- Could not split data in age groups  (N=4)
- No additional data possible (N=4)
Thesis, personal 
communication (N=1)
Potentially relevant articles 
identified in Pubmed (N=236)
Figure 2 Flow diagram of studies included in the review.
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raises the probability of disease by 15% to 20% when
present [48]. Absence of cough and tender anterior cer-
vical adenopathy both decrease the likelihood of
GABHS pharyngitis by 15% to 20% when absent.
A summary ROC curve for signs and symptoms is
presented in Figure 3. The curve and point estimate
are presented as a strong negative correlation was
found between sensitivity and specificity for some of
the signs and symptoms, suggesting the presence of an
implicit threshold effect. The ROC curves are overlap-
ping, suggesting that each of the individual signs and
symptoms included in the analysis have a similar, rela-
tively low ability to discriminate GABHS pharyngitis
patients from other patients presenting with a sore
throat.
Diagnostic test accuracy of the Centor score
Summary estimates for the four levels of Centor cate-
gories show (as expected) increasing specificity and
diminishing sensitivity with higher scores (Table 3).
When ≥ 3 signs or symptoms are present (the recom-
mended cut-off point for empirical antibiotic treat-
ment according to the ACP/ASIM guidelines), the
Centor score has a specificity of 0.82 and a sensitivity
of 0.49 and raises the probability of GABHS in abso-
lute terms by 17% in situations of intermediate pret-
est probability (pretest probability 15%) (Table 4)
[48]. Based on the pooled results, Table 4 shows the
post-test probability of GABHS pharyngitis for a
range of pretest probabilities. If clinicians estimate
t h ep r e v a l e n c eo fG A B H Sp h a r y n g i t i si nt h e i ra r e a ,
this table can be used to find the corresponding post-
test probability of GABHS.
Calibration of the Centor score
There was no significant difference between predicted
and observed events in any of the Centor score cate-
gories (Figure 4), suggesting that the Centor score per-
formed as well in the pooled data at predicting the
probability of culture positive GABHS pharyngitis across
the strata of risk as it did in the derivation study.
Slightly fewer events were predicted in the 0-1 category
than observed (z = 1.69, P = 0.09). There was modest
between-study heterogeneity in the analysis, with I
2
values ranging from 11 to 49%.
A subgroup analysis based on prevalence was carried
out for each score category of the Centor score. The
prevalence was classified as ‘high’ if it was higher than
that reported in the Centor derivation study (17.1%).
The analysis showed that in the 0-1 and 2-3 score
categories fewer events were predicted than observed
in the high prevalence subgroup (0-1 n = 7 RR 0.42,
95% CI 0.25 to 0.70; 2-3 n = 9 RR 0.77, 95% CI 0.60 to
0.98) and slightly more events were predicted than
observed in the low prevalence subgroup (0-1 n = 5
RR 1.11, 95% CI 0.72 to 1.71; 2-3 n = 6 RR 1.43, 95%
CI 1.07 to 1.91). For score category 4, prevalence made
little difference to the performance of the score (high
prevalence n = 9 RR 1.13, 95% CI 0.89 to 1.43 and low
prevalence n = 6 RR 1.20, 95% CI 0.85 to 1.70). Over-
all the subgroup analysis reduced interstudy heteroge-
neity, but did not improve the performance of the
score.
We used the method of Poses et al. [42] to adjust
each study for its own prevalence. We found this
method decreased between-study heterogeneity, but the
predicted-to-observed ratio did not improve significantly
(data not shown).
Table 2 Summary estimates of sensitivity, specificity, positive likelihood ratio (LR) and negative LR calculated for signs
and symptoms using a bivariate random effects model
Sign or symptom No. of
studies
No. of
patients
Sensitivity (95%
CI)
Specificity (95%
CI)
+LR (95% CI) -LR (95% CI)
Absence of cough 19 4,653 0.74 (0.68 to 0.79) 0.49 (0.40 to 0.58) 1.46 (1.28 to
1.66)
0.53 (0.46 to
0.61)
Fever
a 21 4,635 0.50 (0.39 to 0.62) 0.70 (0.58 to 0.79) 1.65 (1.40 to
1.95)
0.71 (0.64 to
0.80)
Anterior cervical adenopathy
b 9 2,101 0.65 (0.55 to 0.74) 0.55 (0.45 to 0.64) 1.45 (1.25 to
1.67)
0.63 (0.52 to
0.76)
Tender anterior cervical
adenopathy
b
16 4,144 0.67 (0.52 to 0.79) 0.59 (0.49 to 0.69) 1.65 (1.41 to
1.92)
0.56 (0.41 to
0.76)
Any exudates
c 21 4,839 0.57 (0.44 to 0.70) 0.74 (0.63 to 0.82) 2.20 (1.76 to
2.74)
0.58 (0.47 to
0.72)
aThe most widely used cut-off point to indicate fever was 38.0°C. Studies also used 37.5°C [40], 37.8°C [37,44,46], 38.3°C [13], 38.5°C [31,45].
bStudies reported on tender lymph nodes, adenopathy or tender adenopathy. All adenopathy results were categorised into tender anterior cervical adenopathy
or anterior cervical adenopathy.
cIncludes results for ‘tonsillar exudate’, ‘pharyngeal exudate’ and ‘exudate’. If both tonsillar and pharyngeal exudate were reported only the results for tonsillar
exudate were added to avoid double counting.
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Principal findings
From the diagnostic test accuracy of signs and symp-
toms analysis, all symptoms and signs included in the
analysis have only a modest ability to discriminate
patients with GABHS pharyngitis from those without it
(range +LR 1.45-2.20, range -LR 0.53-0.71); therefore
no sign or symptom on its own has the power to rule
in or rule out a diagnosis of GABHS pharyngitis. Fever
and ‘any exudates’ have a higher specificity than
sensitivity and are more valid for ruling in a diagnosis
of GABHS pharyngitis when present, while absence of
cough and tender anterior cervical adenopathy have a
higher sensitivity than specificity and are more valid
for ruling out GABHS pharyngitis when absent. Based
on our analysis it could be argued that the signs and
symptoms present in the Centor score could be given
different weights depending on whether the aim of the
physician is to rule in or rule out a diagnosis of
GABHS pharyngitis. However, it is highly unlikely that
Figure 3 Summary receiver operating characteristic (ROC) curve for signs and symptoms.
Table 3 Summary estimates of sensitivity, specificity, positive likelihood ratio (LR) and negative LR for the Centor
score, calculated using a bivariate random effects model
Centor score No. of studies Sensitivity (95% CI) Specificity (95% CI) + LR (95% CI) - LR (95% CI)
≥ 1 11 0.95 (0.91 to 0.97) 0.18 (0.12 to 0.26) 1.16 (1.08 to 1.25) 0.27 (0.16 to 0.46)
≥ 2 12 0.79 (0.71 to 0.86) 0.55 (0.45 to 0.65) 1.76 (1.51 to 2.07) 0.37 (0.29 to 0.48)
≥ 3 11 0.49 (0.38 to 0.60) 0.82 (0.72 to 0.88) 2.68 (1.92 to 3.75) 0.62 (0.52 to 0.74)
4 11 0.18 (0.12 to 0.27) 0.95 (0.92 to 0.97) 3.85 (2.05 to 7.24) 0.86 (0.78 to 0.93)
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s u c has i m p l es c o r e .
In terms of diagnostic accuracy, our analysis of the
Centor score as a decision aid for antibiotic prescribing
suggests that although the score is reasonably specific
when ≥ 3 signs or symptoms are present (0.82) and very
specific when 4 are present (0.95), the post-test prob-
ability of GABHS pharyngitis is relatively low (that is,
for a prevalence of 15% and a score of ≥ 3, post-test
probability is 32%, Table 4). Therefore, although the
Centor score can enhance appropriate prescribing of
antibiotics, it should be used with caution as treating all
patients presenting with a sore throat and a score of ≥ 3
may lead to many patients being treated with antibiotics
inappropriately (Table 4).
In terms of calibration, the Centor score produces
consistent observed:predicted performance across all
risk strata in different populations (Figure 4). This
shows that the Centor score is well calibrated, suggest-
ing that the rule is generalisable across settings and
countries [41].
Findings in the context of other studies
The diagnostic accuracy of signs and symptoms findings
of this systematic review are consistent with a previous
review on GABHS pharyngitis which concluded that no
sign or symptom on its own is powerful enough to rule
in or rule out the diagnosis of GABHS pharyngitis [12].
Not all studies reported the same signs or symptoms to
be of similar predictive value. For example, Lindbaek et
al. and Llor et al. found that among the four Centor cri-
teria, only cervical adenitis and absence of cough were
significantly more frequent in the GABHS pharyngitis
patients compared to those with negative cultures
[33,39], while Meland et al. found that tonsillar exudate
had no predictive ability [35]. Our meta-analysis shows
that all individual symptoms and signs that comprise
the Centor score do have modest discriminatory power,
with ‘any exudates’ being the strongest (Table 2).
To the best of our knowledge, this is the first diagnos-
tic test accuracy review of the Centor score. Wigton et
al. [49] reported that a cut-off point of ≥ 2s i g n so r
symptoms in their patient cohort produced a sensitivity
of 86% and a specificity of 42%, which was similar to
our pooled results (79% and 55% respectively). The
most appropriate cut point for antibiotic treatment
when using the Centor score depends on the clinicians
aim; adults in Western society rarely have complications
such as rheumatic fever and clinicians may want to
ensure a high specificity in the test, which would lead to
lower antibiotic prescription rates but missed cases of
GABHS pharyngitis. Where as a clinician in a develop-
ing country with a high rate of rheumatic fever, and no
access to other diagnostic tests, may feel a high sensitiv-
ity is more important.
Strengths and weaknesses
The strengths of this study include the inclusion of
additional data from authors, and pooling the results of
validation studies for the Centor score so that formal
quantitative validation of the Centor score is
accomplished.
We acknowledge that our review has several limita-
tions: there is moderate heterogeneity in the Centor
score calibration analysis (I
2 = 11% to 49%). Heterogene-
i t yi nt h es t u d i e sc o u l db ed u et oav a r i e t yo ff a c t o r s :
chance; a threshold effect as caused by observer varia-
tion in the measurement of signs and symptoms; a var-
iation in the pretest probability of GABHS pharyngitis;
or other unanticipated factors. The prevalence of
GABHS pharyngitis was highly variable between studies
(Additional file 1). We addressed the effect of study pre-
valence as a source of heterogeneity in our calibration
analysis.
Although we used a systematic search strategy, we
acknowledge that it was not exhaustive and it is possible
that we may have missed relevant articles. In particular,
the use of search filters in systematic reviews is debata-
ble and not always recommended [50].
The use of a throat culture as the reference standard
for diagnosing GABHS pharyngitis is open to some
debate. To date, throat culture is still considered by
most to be the reference standard of choice when diag-
nosing GABHS pharyngitis [3,8]. Newly developed
RADTs can be used in ambulatory care settings, with
results available within minutes [51,52]. However, throat
cultures and RADTs fail to distinguish between active
infection and carriage, which can lead to inappropriate
prescribing of antibiotics for cases of carriage [10,53]. In
addition, many argue that lower sensitivities and the
lack of cost effectiveness of RADTs in primary care, will
limit their use and that signs and symptoms will always
be valuable [54,55].
The method of analysis in pooling the individual Cen-
tor score studies (calibration analysis) is based on the
comparative approach used by Bont et al. to validate the
CRB-65 CPR in a single validation study [56]. This
Table 4 Post-test probability of group A b-haemolytic
streptococcal (GABHS) pharyngitis
Points Likelihood ratio Pretest probability of GABHS pharyngitis
(%)
5 1 01 52 02 53 03 54 0
≥ 1 1.16 6 11 17 22 28 33 38 44
≥ 2 1.76 8 16 24 31 37 43 49 54
≥ 3 2.68 12 23 32 40 47 53 59 64
4 3.85 17 30 40 49 56 62 67 72
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Page 8 of 11method extends and employs the absolute risk from the
derivation study as a model to generate predicted values
in subsequent validation studies. The absolute risk is
presented in CPR risk strata so that the clinical value of
the CPR across these strata can be assessed. Our
method is further supported by an explorative analysis
(unpublished results) that compares our original method
to a validated and published method for comparing pre-
dicted-to-observed values [57]. No statistically significant
difference was found between the predicted events by
the two methods (P > 0.05). A limitation of this method
is that it compares the proportion of patients predicted
and observed to have GABHS pharyngitis but without
patient level data it is not possible to determine if the
positives as predicted by the Centor score are the same
patients who are positive based on the throat swab.
Implications for practice
Our meta-analysis of Centor score suggests that it trans-
fers well to other populations and can be used by
g, ,
a) Centor score 0-1
Study or Subgroup
1.6.1 New Subgroup
Atlas 2005
Canada 2007
Chazan 2003
Jamiel 2005
Johansson 2003
Kljakovic 1993
Lindbaek 2005
McIsaac 1998
McIsaac 2000
Meland 1993
Rosenberg 2002
Treebupachatsakul 2006
Events
3
2
4
2
5
9
3
14
14
2
1
3
Total
55
31
78
35
93
150
58
295
303
39
29
57
Events
6
3
4
1
19
7
11
10
14
5
1
6
Total
55
31
78
35
93
150
58
295
303
39
29
57
Weight
7.1%
4.6%
6.9%
2.6%
12.1%
11.8%
8.1%
15.3%
17.2%
5.3%
1.9%
7.1%
M-H, Random, 95% CI
0.50 [0.13, 1.90]
0.67 [0.12, 3.72]
1.00 [0.26, 3.86]
2.00 [0.19, 21.06]
0.26 [0.10, 0.68]
1.29 [0.49, 3.36]
0.27 [0.08, 0.93]
1.40 [0.63, 3.10]
1.00 [0.49, 2.06]
0.40 [0.08, 1.94]
1.00 [0.07, 15.24]
0.50 [0.13, 1.90]
Predicted Observed Risk Ratio Risk Ratio
M-H, Random, 95% CI
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.09; Chi² = 13.82, df = 11 (P = 0.24); I² = 20%
Test for overall effect: Z = 1.69 (P = 0.09)
Test for subgroup differences: Not applicable
62
1223
87
1223 100.0% 0.72 [0.49, 1.06]
0.05 0.2 1 5 20
predicted<observed predicted>observed
b) Centor score 2 
Study or Subgroup
Atlas 2005
Canada 2007
Humair 2006
Jamiel 2005
Johansson 2003
Kljakovic 1993
Lindbaek 2005
Llor 2008
McIsaac 1998
McIsaac 2000
Meland 1993
Rosenberg 2002
Seppela 1993
Treebupachatsakul 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.21; Chi² = 25.25, df = 13 (P = 0.02); I² = 49%
Test for overall effect: Z = 0.66 (P = 0.51)
Events
7
7
23
4
5
10
10
10
14
10
2
2
5
3
112
Total
45
43
148
24
32
65
68
63
89
67
16
14
33
21
728
Events
16
5
35
2
11
9
30
5
9
10
4
1
1
2
140
Total
45
43
148
24
32
65
68
63
89
67
16
14
33
21
728
Weight
9.4%
6.9%
13.1%
4.0%
8.0%
9.0%
11.2%
7.3%
9.5%
9.2%
4.2%
2.2%
2.6%
3.7%
100.0%
M-H, Random, 95% CI
0.44 [0.20, 0.96]
1.40 [0.48, 4.07]
0.66 [0.41, 1.06]
2.00 [0.40, 9.91]
0.45 [0.18, 1.16]
1.11 [0.48, 2.55]
0.33 [0.18, 0.63]
2.00 [0.72, 5.52]
1.56 [0.71, 3.41]
1.00 [0.45, 2.24]
0.50 [0.11, 2.35]
2.00 [0.20, 19.62]
5.00 [0.62, 40.51]
1.50 [0.28, 8.08]
0.88 [0.61, 1.27]
Predicted Observed Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Predicted < observed predicted > observed
c) Centor score 3  
Study or Subgroup
Atlas 2005
Canada 2007
Humair 2006
Jamiel 2005
Johansson 2003
Kljakovic 1993
Lindbaek 2005
Llor 2008
McIsaac 1998
McIsaac 2000
Meland 1993
Rosenberg 2002
Seppela 1993
Treebupachatsakul 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 14.54, df = 13 (P = 0.34); I² = 11%
Test for overall effect: Z = 0.44 (P = 0.66)
Events
9
12
49
8
3
9
21
26
11
12
4
6
5
3
178
Total
30
39
156
26
9
27
66
83
35
37
13
20
16
8
565
Events
10
13
64
2
5
3
29
21
9
10
5
7
3
3
184
Total
30
39
156
26
9
27
66
83
35
37
13
20
16
8
565
Weight
6.1%
7.9%
26.1%
1.7%
3.0%
2.5%
14.8%
12.8%
6.1%
6.8%
3.1%
4.4%
2.3%
2.3%
100.0%
M-H, Random, 95% CI
0.90 [0.43, 1.90]
0.92 [0.48, 1.76]
0.77 [0.57, 1.03]
4.00 [0.94, 17.07]
0.60 [0.20, 1.79]
3.00 [0.91, 9.89]
0.72 [0.46, 1.13]
1.24 [0.76, 2.02]
1.22 [0.58, 2.58]
1.20 [0.59, 2.43]
0.80 [0.28, 2.32]
0.86 [0.35, 2.10]
1.67 [0.48, 5.83]
1.00 [0.28, 3.54]
0.96 [0.79, 1.16]
Predicted Observed Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
predicted < observed predicted > observed
d) Centor score 4
Study or Subgroup
Atlas 2005
Canada 2007
Chazan 2003
Humair 2006
Jamiel 2005
Johansson 2003
Kljakovic 1993
Lindbaek 2005
Llor 2008
McIsaac 1998
McIsaac 2000
Meland 1993
Rosenberg 2002
Seppela 1993
Treebupachatsakul 2006
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 15.69, df = 14 (P = 0.33); I² = 11%
Test for overall effect: Z = 1.36 (P = 0.17)
Events
10
15
8
38
12
2
5
12
20
6
9
3
4
3
4
151
Total
18
27
14
68
21
4
9
22
36
10
17
6
7
5
8
272
Events
6
13
2
41
6
4
3
10
14
5
11
2
5
1
4
127
Total
18
27
14
68
21
4
9
22
36
10
17
6
7
5
8
272
Weight
5.3%
10.7%
1.8%
25.3%
5.3%
3.8%
2.8%
8.4%
11.2%
5.0%
9.1%
1.7%
5.0%
0.9%
3.4%
100.0%
M-H, Random, 95% CI
1.67 [0.77, 3.61]
1.15 [0.69, 1.93]
4.00 [1.03, 15.60]
0.93 [0.70, 1.23]
2.00 [0.93, 4.32]
0.56 [0.22, 1.40]
1.67 [0.56, 4.97]
1.20 [0.66, 2.18]
1.43 [0.86, 2.36]
1.20 [0.54, 2.67]
0.82 [0.46, 1.45]
1.50 [0.38, 6.00]
0.80 [0.36, 1.77]
3.00 [0.45, 19.93]
1.00 [0.38, 2.66]
1.14 [0.95, 1.37]
Predicted Observed Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
predicted < observed predicted > observed
Notes:  Meland 1993 reported the proportion of group A positive cultures versus group C and G in their study. After doing a 
sensitivity analysis, we adjusted the results using the percentage of group A when estimating the number of observed GABHS
positive patients. Kljakovic 1993 did not report the group (A, C or G) for cultures positive for streptococci. After a sensitivity 
analysis we assumed that all positive cultures were group A, as the overall prevalence in this study was relatively low. 
Figure 4 Forest plots of Centor scores 0-1, 2, 3 and 4.
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Page 9 of 11clinicians to make informed decisions (Table 4 and Fig-
ure 4). However, the relatively low post-test probability
of GABHS pharyngitis even in areas of high prevalence
(Table 4), suggests the score should be used with cau-
tion by clinicians when used as a decision aid for anti-
biotic prescribing. Studies have shown that the use of
scores can improve antibiotic prescribing [14], while
others have found them no better than clinician judge-
ment [58].
A barrier when introducing CPRs such as the Cen-
tor score into practice is that clinicians often fail to
apply them [59,60]. One community-based study that
used repeated clinical prompts for the modified Cen-
tor score to try and influence physician’s behaviour
when prescribing antibiotics for sore throats, found no
significant change in physician behaviour [60]. How-
ever, the authors had problems retaining community-
based physicians for the duration of the study and
believe their results may have been biased by these
losses [60].
The formal incorporation of CPRs can be facilitated by
computer-based clinical decision support systems
( C D S S s )t h a tq u a n t i f yd i a g n ostic and prognostic infor-
mation so as to provide physicians with patient specific
recommendations: such aids have been shown to reduce
antibiotic prescribing in respiratory tract infections in
children in primary care settings [61,62].
Conclusions
Individual symptoms and signs have only a modest
ability to rule in or out a diagnosis of GABHS pharyn-
gitis. The Centor score uses a combination of signs
and symptoms to predict the risk of GABHS pharyngi-
tis; the score is well calibrated across a variety of coun-
tries and settings. It has reasonably good specificity,
and can enhance the appropriate prescribing of anti-
biotics, but should be used with caution in low preva-
lence settings of GABHS pharyngitis such as primary
care.
Additional material
Additional file 1: Table S1. Summary of included studies.
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